42 results about "Psychotic illness" patented technology

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The invention discloses a pharmaceutical composition for improving biphasic depression and a pharmaceutical preparation and application thereof, and belongs to the technical field of research and development of biphasic depression drugs, the pharmaceutical composition is composed of nicotine and a second-generation antipsychotic drug, and the second-generation antipsychotic drug is quetiapine or risperidone. Experiments prove that the combined use of the nicotine and the second-generation antipsychotic has a synergistic effect in the aspect of improving the manic behavior of biphasic depression and has a better effect of improving the biphasic depression compared with the independent use of the nicotine and the second-generation antipsychotic.

Combination compositions of Compound 1 and fesoterodine for use in the treatment of neurological disorders, such as schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia, are described.

The invention relates to a cancer patient mental health prediction model based on multi-source data and application. The model comprises the following steps: utilizing electronic health record (EHR) data and longitudinal data of cancer patients in prospective queue research; constructing and verifying a prediction model in combination with multiple factors; carrying out model training and verification by utilizing a machine learning algorithm so as to realize early prediction of anxiety, depression and psychotic disorders; and quantifying the contribution of each factor to the psychological health risk through model interpretive analysis. Through multi-source data fusion and an advanced algorithm, the early recognition rate of the psychological health problem of the cancer patient can be effectively improved, resource waste and diagnosis delay are reduced, and the treatment effect and life quality of the patient are improved.

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and / or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

The invention relates generally to improvements in the treatment of psychotic symptoms, and more particularly, to improvements in the identification of an individual or a population of individuals for whom treatment with iloperidone, an iloperidone metabolite, or pharmaceutically-acceptable salts thereof may provide a particular benefit in treating an individual's psychotic symptoms based on the individual's genotype at the PPEF2 locus.

The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses, and central nervous system (CNS) disorders.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

Compositions and methods for treating psychosis or a psychotic disorder with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of psychosis or a psychotic disorder.or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The present application relates to a compound as shown in formula (I), stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, and preparation method and pharmaceutical composition. The compound is an NK-3 receptor antagonist, which can be used for preventing and / or treating depression, anxiety, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory disease, vomiting, preeclampsia, airway related disease, reproductive disorder, contraception and sex hormone dependent disease, gynecological disease related disease, menopausal syndrome related disease.

The invention provides application of a chalcone compound as well as a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof in preparation of a medicament for treating depression. The depression is selected from mild depression, moderate depression, severe depression, persistent depressive disorder, depression associated with bipolar disorder, seasonal affective disorder, psychotic depression, postpartum depression, premenstrual anxiety disorder, encountering depression, pleasant sensation deficiency, melancholia, middle-year depression and late-year depression; depression caused by identifiable pressure factors, refractory depression, or a combination thereof. The compounds can treat mental symptoms of depression, such as depressive mood and loss of interest or fun in almost all activities.

The invention discloses an application of combination of nicotine and a second-generation antipsychotic in preparation of drugs for relieving bipolar depression, and belongs to the technical field of research and development of drugs for relieving bipolar depression. Experiments prove that compared with single use of nicotine and second-generation antipsychotic, the combined use of nicotine and second-generation antipsychotic in the invention has the advantages that the use amount of nicotine and second-generation antipsychotic is reduced; the nicotine and the second-generation antipsychotic have synergistic interaction in the aspect of improving manic behaviors of bipolar depression and have a better effect of improving bipolar depression, and the application of the combination of nicotine and the second-generation antipsychotic in preparation of the medicine for relieving bipolar depression provides experimental basis and scientific support for clinical treatment of bipolar depression.

The invention relates to the technical field of depression resistance, in particular to a pharmaceutical composition and application thereof. According to the application disclosed by the invention, low-dose non-addictive dose nicotine is combined with an antipsychotic drug such as olanzapine to investigate the influence of the nicotine on the bipolar depression, so that the treatment effect on the bipolar depression can be synergistically improved, and the side effect caused by the antipsychotic drug is reduced.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

This document describes a combination composition of compound 1 and fesoterodine for treating neurological disorders (e.g., schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive impairment in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia).

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

The application provides a traditional Chinese medicine composition for treating depression, a traditional Chinese medicine preparation and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises Astragalus membranaceus, Bupleurum chinense, Atractylodes macrocephala, Suanzaoren, Crocus sativus, Atractylodes lancea and Glycyrrhiza uralensis. The above-mentioned drugs are combined in the application, and jointly play the functions of activating qi and soothing liver, promoting blood circulation and relieving depression, especially can improve depression induced or aggravated by improper emotion and accompanied by psychotic symptoms, are suitable for clinical popularization and application, and have wide application prospect.

N-([1,1'-biaryl]-4-yl)-N-((1-hydroxycycloalkyl)methyl)-2-(aryl)cyclopropane-1-carboxamide compounds (I) and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, tardive dyskinesia, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease, basal ganglia disorders, and tardive dyskinesia.

The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses, and central nervous system (CNS) disorders. Formula (I)

An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt % of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt % of a disintegrant, between 0.1 and 5 wt % of colloidal silicon dioxide, between 0.1 and 10 wt % of a taste masking agent, between 0.1 and 5 wt % of a lubricant, and up to 100 wt % of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

A method of treatment of mental disorder of a subject includes the steps of: normalizing an expression of both DRD1 and DRD5, which belong to DRD1-like family, of the subject to a preset standard level. The DRD1 / 5 level and expression can be increased or decreased bidirectionally by targeting an upstream promoter sequence of DRD1 / 5. The promoter activity of DRD1 / 5 can be attenuated by using an antipsychotic which directly targets the DRD1 / 5 promoter. The antipsychotics being used are typical and / or atypical antipsychotic medications such as Haloperidol,Risperidone, Clozapine and Cariprazine. The treatment is also useful for the subject with an impaired constitutive expression of DRD1 / 5 gene. The method can be used to treat schizophrenia, autism, depression, mania and bipolar disorders by normalizing the DRD1 / 5 expression level. The promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening through comparing with a standard sequence database.

The present invention relates to a depression diagnosis system using multiparadigm brainwaves and machine learning. According to one embodiment of the present invention, a depression diagnosis system using multiparadigm brainwaves and machine learning may include: a brainwave measurement unit that measures a plurality of paradigm brainwaves from a subject; a brainwave extraction unit that extracts and preprocesses necessary multiparadigm brainwaves from the measured plurality of paradigm brainwaves to minimize noise; a model generation unit that creates a diagnosis model by performing machine learning using the extracted multiparadigm brainwaves; and a diagnosis unit that diagnoses the presence of depression using the generated diagnosis model. As such, according to the present invention, by generating a diagnostic model of a subject using multiparadigm brainwaves and diagnosing the presence of depression, the limitations of conventional diagnostic classification using a single paradigm can be overcome. Furthermore, by generating and applying a model through machine learning using multiple key brainwave biomarker data, the classification performance of depression with psychopathological diversity can be enhanced.

1,5-dihydro-2,4-benzodiazepine-3-one derivatives, such as a compound represented by formula I, acts on 5-HT2A and 5-HT2C receptors. The selectivity for 5-HT2A is superior or similar to pimavanserin. The derivative is used for treating schizophrenia or Parkinson's disease, dementia-related behavioral disorders, and psychosis. The antipsychotic activity of the compound is equivalent to that of pimavanserin, the side effects of sedation and worsening of exercise are less than those of pimavanserin, and cardiotoxicity is less than that of pimavanserin.